These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35993234)

  • 1. Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer: early results of a multicenter phase IIB study.
    Riesterer O; Ademaj A; Puric E; Eberle B; Beck M; Gomez S; Marder D; Oberacker E; Rogers S; Hälg RA; Kern T; Schwenne S; Stein J; Stutz E; Timm O; Zschaeck S; Weyland MS; Veltsista PD; Wyler S; Wust P; Scheidegger S; Bodis S; Ghadjar P
    Int J Hyperthermia; 2022; 39(1):1078-1087. PubMed ID: 35993234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2).
    Merten R; Ott O; Haderlein M; Bertz S; Hartmann A; Wullich B; Keck B; Kühn R; Rödel CM; Weiss C; Gall C; Uter W; Fietkau R
    Oncologist; 2019 Dec; 24(12):e1341-e1350. PubMed ID: 31292267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients.
    Kijima T; Tanaka H; Koga F; Masuda H; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
    BJU Int; 2019 Aug; 124(2):242-250. PubMed ID: 30811784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes of Patients With Histologic Variants of Urothelial Carcinoma Treated With Selective Tetramodal Bladder-preservation Therapy Incorporating Consolidative Partial Cystectomy.
    Kijima T; Tanaka H; Uehara S; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Kihara K; Fujii Y
    Clin Genitourin Cancer; 2020 Aug; 18(4):268-273.e2. PubMed ID: 31883941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia.
    Wittlinger M; Rödel CM; Weiss C; Krause SF; Kühn R; Fietkau R; Sauer R; Ott OJ
    Radiother Oncol; 2009 Nov; 93(2):358-63. PubMed ID: 19837472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiotherapy combined with deep regional hyperthermia in elderly and frail patients with muscle-invasive bladder cancer: quality analysis of hyperthermia and impact on clinical results.
    Ademaj A; Puric E; Marder D; Timm O; Kern T; Hälg RA; Rogers S; Riesterer O
    Int J Hyperthermia; 2023; 40(1):2275540. PubMed ID: 37932002
    [No Abstract]   [Full Text] [Related]  

  • 7. Renal function outcome after selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and consolidative partial cystectomy in comparison with radical cystectomy for patients with muscle-invasive bladder cancer: a two-centre retrospective study.
    Fujiwara M; Yokoyama M; Toide M; Fujiwara R; Tanaka H; Oguchi T; Komai Y; Yoshida S; Matsuoka Y; Numao N; Yamamoto S; Fukui I; Yonese J; Fujii Y
    Jpn J Clin Oncol; 2023 Mar; 53(3):263-269. PubMed ID: 36524369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival.
    Lee CY; Yang KL; Ko HL; Huang RY; Tsai PP; Chen MT; Lin YC; Hwang TI; Juang GD; Chi KH
    Radiat Oncol; 2014 Sep; 9():213. PubMed ID: 25248470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response.
    Kaufman DS; Winter KA; Shipley WU; Heney NM; Chetner MP; Souhami L; Zlotecki RA; Sause WT; True LD
    Oncologist; 2000; 5(6):471-6. PubMed ID: 11110598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial results of retrospective study: preoperative transurethral excision plus chemotherapy and radiation therapy and trial of bladder preservation.
    Gamal El-Deen HS
    J Egypt Natl Canc Inst; 2007 Jun; 19(2):133-46. PubMed ID: 19034344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and outcomes of selective tetramodal bladder-preservation therapy in elderly patients with muscle-invasive bladder cancer.
    Tanaka H; Fukushima H; Kijima T; Nakamura Y; Yajima S; Uehara S; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Saito K; Fujii Y
    Int J Urol; 2020 Mar; 27(3):236-243. PubMed ID: 31957164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy.
    Suer E; Hamidi N; Gokce MI; Gulpinar O; Turkolmez K; Beduk Y; Baltaci S
    World J Urol; 2016 Jun; 34(6):847-51. PubMed ID: 26462931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organ-sparing treatment in muscle-invasive bladder cancer.
    Dunst J; Diestelhorst A; Kühn R; Müller AC; Scholz HJ; Fornara P
    Strahlenther Onkol; 2005 Oct; 181(10):632-7. PubMed ID: 16220401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
    Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
    Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.
    Rödel C; Grabenbauer GG; Kühn R; Papadopoulos T; Dunst J; Meyer M; Schrott KM; Sauer R
    J Clin Oncol; 2002 Jul; 20(14):3061-71. PubMed ID: 12118019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bladder preservation using chemoradiation therapy for locally invasive bladder cancer].
    Abe T; Yoshioka T; Sato M; Mori N; Sekii K; Itatani H
    Nihon Hinyokika Gakkai Zasshi; 2011 Jan; 102(1):14-22. PubMed ID: 21520632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder preservation by combined modality therapy for invasive bladder cancer.
    Kachnic LA; Kaufman DS; Heney NM; Althausen AF; Griffin PP; Zietman AL; Shipley WU
    J Clin Oncol; 1997 Mar; 15(3):1022-9. PubMed ID: 9060542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary results of treatment of invasive bladder carcinoma with radiotherapy and cisplatin.
    Sauer R; Schrott KM; Dunst J; Thiel HJ; Hermanek P; Bornhof C
    Int J Radiat Oncol Biol Phys; 1988 Oct; 15(4):871-5. PubMed ID: 3182327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is hyperthermia combined with radiotherapy adequate in elderly patients with muscle-invasive bladder cancers? Thermo-radiobiological implications from an audit of initial results.
    Datta NR; Eberle B; Puric E; Meister A; Marder D; Tim O; Klimov A; Bodis S
    Int J Hyperthermia; 2016 Jun; 32(4):390-7. PubMed ID: 26795033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer.
    Chen WC; Liaw CC; Chuang CK; Chen MF; Chen CS; Lin PY; Chang PL; Chu SH; Wu CT; Hong JH
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):726-33. PubMed ID: 12788178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.